CADL

Candel Therapeutics, Inc.

7.59 USD
+0.01 (+0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Candel Therapeutics, Inc. stock is down -29.07% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 May 17:22 18 Oct, 2024 12.00 CALL 200 45
13 May 16:45 18 Oct, 2024 12.00 CALL 88 247
13 May 17:04 21 Jun, 2024 8.00 PUT 800 3
14 May 13:30 18 Oct, 2024 12.00 CALL 100 483
15 May 18:21 21 Jun, 2024 12.00 CALL 236 395
16 May 13:31 21 Jun, 2024 15.00 CALL 1990 2066
16 May 15:26 18 Oct, 2024 15.00 CALL 110 14
17 May 15:25 19 Jul, 2024 12.00 CALL 300 22
24 May 14:10 17 Jan, 2025 8.00 CALL 100 1
04 Jun 15:15 18 Oct, 2024 8.00 PUT 198 15

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.